Heterogeneity of mitotic activity in breast cancer

Histopathology

Volumn 29, Issue 5, 1996, Pages 421-428

  Jannink, I ^a   Risberg, B ^b   Van Diest, P J ^a   Baak, J P A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Breast cancer; Heterogeneity; Proliferation

Indexed keywords

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MITOSIS; MORPHOMETRICS; PRIORITY JOURNAL;

EID: 0029824447     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.d01-509.x     Document Type: Article

References (42)

1. Aaltomaa S, Lipponen P, Eskelinen M et al. Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer. Int. J. Cancer 1991; 49: 886-892.
2. Baak JPA, Diest PJ van, Benraadt T et al. The multicenter morphometric mammary carcinoma project (MMMCP) in The Netherlands: value of morphometrically assessed proliferation and differentiation. J. Cell. Biochem. 1993; 17G; 220-225.
3. Baak JPA, Dop H van, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56; 374-382.
4. Baak JPA, Kurver PHJ, De Snoo-Nieuwlaat AJE et al. Prognostic indicators in breast cancer-morphometric methods. Histopathol. 1982; 6; 327-339.
5. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer 1991; 68: 1309-1317.
6. Diest PJ van, Baak JPA. The morphometric multivariate prognostic index (MPI) is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients. Hum. Pathol. 1991; 22; 326-330.
7. Diest PJ van, Baak JPA et al. Reproducibility of mitoses counting in 2469 breast cancer specimens; Results from the Multicenter Morphometric Mammary Carcinoma Project. Hum. Pathol. 1992; 23; 603-607.
8. Haapasalo H, Collan Y, Pesonen E. Volume corrected mitotic index (M/V index); the standard of mitotic activity in neoplasms. Pathol. Res. Prac. 1989; 185; 551-554.
9. Hilsenbeck SG, Allred DG. Improved methods of estimating mitotic activity in solid tumours. Hum. Pathol, 1992; 23; 601-602.
10. Joensuu H, Toikkanen S, Klemi PJ. DNA Index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer 1990; 66; 331-340.
11. Laroye GJ, Minkin S. The impact of mitotic index on predicting outcome in breast carcinoma; a comparison of different counting methods in patients with different lymph node status. Modern Pathol. 1991; 4; 456-460.
12. Linden JC van der, Baak JPA, Lindeman J, Hermans J, Meijer CJLM. Prospective evaluation of the prognostic value of morphometry in primary breast cancer patients. J. Clin. Pathol. 1987; 40; 302-306.
13. Linden JC van der, Lindeman J, Baak JPA, Meijer CJLM, Herman CJ. The multivariate prognostic index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry 1989; 10; 56-61.
14. Lipponen PK, Collan Y, Eskelinen MJ. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer. Int. Surg. 1991; 76; 245-249.
15. Russo J, Frederick J, Ownby HE et al. Predictors of recurrence and survival of patients with breast cancer. Am. J. Clin. Pathol. 1987; 88; 123-131.
16. Tosi P, Luzi P, Sforza V et al. Correlation between morphometrical parameters and disease free-survival in ductal breast cancer treated by only surgery. Appl. Pathol. 1986; 4; 33-42.
17. Uyterlinde AM, Baak JPA, Schipper NW, Peterse H, Matze E, Meijer CJLM. Further evaluation of the prognostic value of morphometric and flow cytometric features in breast cancer patients with long term follow up. Int. J. Cancer 1990; 45; 1-7.
18. Uyterlinde AM, Schipper NW, Baak JPA. Comparison of extent of disease and morphometric and DNA flow cytometric prognostic factors in invasive ductal breast cancer. J. Clin. Pathol. 1987; 40; 1432-1436.
19. Uyterlinde AM, Schipper NW, Baak JPA, Peterse H, Matze E. Limited prognostic value of cellular DNA content to classical and morphometric parameters in invasive ductal breast cancer. Am. J. Clin. Pathol. 1988; 86; 301-307.
20. Donhuijsen K. Mitosis counts; Reproducibility and significance in grading of malignancy. Hum. Pathol. 1986; 17; 1122-1125.
21. Montironi R, Collan Y, Scarpelli M et al. Reproducibility of mitotic figures in malignant glial tumours. Appl. Pathol. [APP] 1988; 6; 258-265.
22. Jannink I, Diest PJ van, Baak JPA. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients; classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum. Pathol. 1995; 26; 1086-1092.
23. Bullough WS. Mitotic activity in the tissues of dead mice and in tissues kept in physiological salt solutions. Exp. Cell. Res. 1950; 1; 410-420.
24. Cross SS, Start RD, Smith JHF. Does delay in fixation affect the number of mitotic figures in processed tissues? J. Clin. Pathol. 1990; 43; 597-599.
25. Edwards JL, Donalson JT. The time of fixation and the mitotic index. Am. J. Clin. Pathol. 1964; 41; 158-162.
26. Graem N, Helweg-Larsen K. Mitotic activity and delay in fixation of tumor tissue. Acta. Pathol. Microbiol. Scand. 1979; 87; 375-378.
27. Start RD, Flynn MS, Cross SS, Rogers K, Smith JHF. Is the grading of breast carcinomas affected by a delay in fixation? Vichows Archiv A. Pathol. Anat. 1991; 419; 475-477.
28. Bergers E, Jannink I, Diest PJ van et al. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables, in press.
29. Donhuijsen K, Schmidt U, Hirche H, Beuningen D van, Budach V. Changes in mitotic rate and cell cycle fractions caused by delay in fixation. Hum. Pathol. 1990; 21; 709-714.
30. Evans N. Mitotic figures in malignant tumors as affected by time before fixation of tissues. Arch. Pathol. Lab. Med. 1926; 1; 894-898.
31. Verhoeven D, Bourgeois N, Derde MP, Kaufman L, Buyssens N. Comparison of cell growth in different parts of breast cancers. Histopathol. 1990; 17; 505-509.
32. Baak JPA. Counting mitosis (Editorial). Hum. Pathol. 1990; 21; 683-685.
33. Aherne WA, Camplejohn RS, Al-Wiswasy M, Ford D, Kellerer AM. Assessment of inherent fluctuations of mitotic and labelling indices of human tumours. Br. J. Cancer 1977; 36; 577-582.
34. Baak JPA. A Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. NY Heidelberg, Springer, 1991.
35. Baak JPA, Noteboom E, Koevoets JJM. The influence of fixatives and other variations in tissue processing on nuclear morphometric features. Analyt. Quant. Cytol. Histol. 1989; 11; 219-224.
36. Baak JPA, Oort J. A manual of morphometry in diagnostic pathology. Springer, Heidelberg, Berlin, New York, 1983.
37. Sokal RR, Rohlf FJ. Biometry. W H Freeman and Company. New York. Second edition, 1981.
38. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217; 998-1003.
39. Heppner GH. Tumor heterogeneity. Cancer Res. 1984; 44; 2259-2265.
40. Heppner GH. Cancer cell societies and tumour progression. Stem Cells 1993; 11; 199-203.
41. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194; 23-28.
42. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathol. 1991; 19; 403-410.